Mathematical Modelling of Spatio-temporal Phenomena in Tumour Immunology

Cancer still remains one of the most difficult diseases to treat clinically and is one of the main causes of mortality in developed western societies. The mortality statistics for the United Kingdom for the year 2002 show that 155,180 people were registered as dying from a malignant neoplasm.1 This figure represents 26% of all causes of death in the UK for 2002. Similar statistics hold for the United States as can be seen in Fig. 1, which shows the main causes of death in the USA during the two years 1975 and 2001.

[1]  M. Bar‐eli.  Role of Interleukin-8 in Tumor Growth and Metastasis of Human Melanoma , 1999, Pathobiology.

[2]  Lawrence F. Shampine,et al.  The MATLAB ODE Suite , 1997, SIAM J. Sci. Comput..

[3]  K. Hellström,et al.  Cellular immunity against tumor antigens. , 1969, Advances in cancer research.

[4]  G. Klein,et al.  Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. , 1960, Cancer research.

[5]  Luigi Preziosi,et al.  Modelling Tumor Progression, Heterogeneity, and Immune Competition , 2002 .

[6]  R. Puri,et al.  Interleukin-4 and cancer therapy. , 1993, Cancer investigation.

[7]  F. Shanahan,et al.  The Fas counterattack: cancer as a site of immune privilege. , 1999, Immunology today.

[8]  J. Ghiso.  Inhibition of FAK signaling activated by urokinase receptor induces dormancy in human carcinoma cells in vivo , 2002, Oncogene.

[9]  D. Bostwick,et al.  Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen , 1998, Cancer.

[10]  B. Chapuis,et al.  Quantitative assay of the lytic action of immune lymphoid cells on 51-Cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs. , 1968, Immunology.

[11]  D. Drasdo,et al.  Individual-based approaches to birth and death in avascu1ar tumors , 2003 .

[12]  René Lefever,et al.  Stability problems in cancer growth and nucleation , 1980 .

[13]  R. Sutherland.  Cell and environment interactions in tumor microregions: the multicell spheroid model. , 1988, Science.

[14]  K. Okuno,et al.  FBL-reactive CD8+ cytotoxic and CD4+ helper T lymphocytes recognize distinct Friend murine leukemia virus-encoded antigens , 1989, The Journal of experimental medicine.

[15]  J. Wharton,et al.  Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines , 1995, The Journal of experimental medicine.

[16]  J. Sherratt,et al.  Cells behaving badly: a theoretical model for the Fas/FasL system in tumour immunology. , 2002, Mathematical biosciences.

[17]  Rene Lefever,et al.  On the Growth of Cellular Tissues Under Constant and Fluctuating Environmental Conditions , 1984 .

[18]  R. Weger,et al.  Immune reactivity in SL2 lymphoma-bearing mice compared with SL2-immunized mice , 2004, Cancer Immunology, Immunotherapy.

[19]  R. Zinkernagel,et al.  Inflammatory process in murine lymphocytic choriomeningitis is maximal in H-2K or H-2D compatible interactions. , 1976, Journal of immunology.

[20]  M. Herlyn,et al.  Melanoma cells and normal melanocytes share antigens recognized by HLA- A2-restricted cytotoxic T cell clones from melanoma patients , 1993, The Journal of experimental medicine.

[21]  P. Friedl,et al.  T lymphocyte locomotion in a three-dimensional collagen matrix. Expression and function of cell adhesion molecules. , 1995, Journal of immunology.

[22]  R. Prehn,et al.  Immunity to methylcholanthrene-induced sarcomas. , 1957, Journal of the National Cancer Institute.

[23]  W. Clark,et al.  The biologic forms of malignant melanoma. , 1986, Human pathology.

[24]  P. Resnitzky,et al.  Variations in surface charge distribution of leukemic and non-leukemic transformed cells. , 1988, Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis.

[25]  D. Loeffler,et al.  In vivo localization of lymphocytes labelled with low concentrations of Hoechst 33342. , 1989, Journal of immunological methods.

[26]  G. Fleuren,et al.  Immunotherapeutic strategies for cervical squamous carcinoma. , 1999, Hematology/oncology clinics of North America.

[27]  G. Naumov,et al.  Persistence of solitary mammary carcinoma cells in a secondary site: a possible contributor to dormancy. , 2002, Cancer research.

[28]  L. Old,et al.  ANTIGENIC PROPERTIES OF CHEMICALLY INDUCED TUMORS * , 1962 .

[29]  M. Retsky,et al.  Prospective computerized simulation of breast cancer: comparison of computer predictions with nine sets of biological and clinical data. , 1987, Cancer research.

[30]  G. Forni.  Tumor-host relationship: The viewpoint of an immunologist towards applied mathematicians , 1996 .

[31]  K. Resch,et al.  Characterization of cellular and extracellular plasma membrane vesicles from a non-metastasizing lymphoma (Eb) and its metastasizing variant (ESb). , 1985, Biochimica et biophysica acta.

[32]  M. Herlyn,et al.  Insulin-like growth factor-I-induced migration of melanoma cells is mediated by interleukin-8 induction. , 2002, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[33]  H. Nishiura,et al.  Human CC chemokine liver-expressed chemokine/CCL16 is a functional ligand for CCR1, CCR2 and CCR5, and constitutively expressed by hepatocytes. , 2001, International immunology.

[34]  L. Holmberg,et al.  Work on your theories! , 1996, Nature Medicine.

[35]  S. Cox,et al.  Modelling Macrophage Infiltration into Avascular Tumours , 2002 .

[36]  R. Henderson,et al.  MUC‐1 Epithelial Tumor Mucin‐Based Immunity and Cancer Vaccines , 1995, Immunological reviews.

[37]  G. Weisbuch,et al.  Immunology for physicists , 1997 .

[38]  P. Kourilsky,et al.  Retrovirus antigens recognized by cytolytic T lymphocytes activate tumor rejection in vivo , 1987, Cell.

[39]  J. Schlom,et al.  Carcinoembryonic antigen as a target for cancer vaccines , 1996, Cancer Immunology, Immunotherapy.

[40]  J A Sherratt,et al.  Pattern formation and spatiotemporal irregularity in a model for macrophage-tumour interactions. , 1997, Journal of theoretical biology.

[41]  G. D. Knott,et al.  Modeling tumor regrowth and immunotherapy , 2001 .

[42]  R. D'Amato,et al.  Persistence of microscopic human cancers in mice: alterations in the angiogenic balance accompanies loss of tumor dormancy , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[43]  Nicola Bellomo,et al.  The modelling of the immune competition by generalized kinetic (Boltzmann) models: Review and research perspectives , 2003 .

[44]  L. Preziosi,et al.  Modelling and mathematical problems related to tumor evolution and its interaction with the immune system , 2000 .

[45]  G. Murphy,et al.  Vaccine therapy for prostate cancer. , 1999, The Urologic clinics of North America.

[46]  Nicola Bellomo,et al.  A Survey of Models for Tumor-Immune System Dynamics , 1996 .

[47]  B. Fenton,et al.  Alteration of tumour response to radiation by interleukin-2 gene transfer , 2000, British Journal of Cancer.

[48]  M A Lewis,et al.  Ecological chaos in the wake of invasion. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[49]  Mark A J Chaplain,et al.  Mathematical modelling of the spatio-temporal response of cytotoxic T-lymphocytes to a solid tumour. , 2004, Mathematical medicine and biology : a journal of the IMA.

[50]  R. Sutherland,et al.  Growth and cellular characteristics of multicell spheroids. , 1984, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[51]  D. Laface,et al.  Identification of Her-2/Neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD.8. , 1997, Human immunology.

[52]  J. Xiang,et al.  Lymphotactin Expression by Engineered Myeloma Cells Drives Tumor Regression: Mediation by CD4+ and CD8+ T Cells and Neutrophils Expressing XCR1 Receptor1 , 2001, The Journal of Immunology.

[53]  M. Chaplain,et al.  Travelling-wave analysis of a model of the immune response to cancer. , 2004, Comptes rendus biologies.

[54]  S. Rosenberg,et al.  Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[55]  A. Mantovani,et al.  The signal transduction pathway involved in the migration induced by a monocyte chemotactic cytokine. , 1991, Journal of immunology.

[56]  Nicola Bellomo,et al.  BIFURCATION ANALYSIS FOR A NONLINEAR SYSTEM OF INTEGRO-DIFFERENTIAL EQUATIONS MODELLING TUMOR-IMMUNE CELLS COMPETITION , 1999 .

[57]  G. Merlo,et al.  Frequent alteration of the DF3 tumor-associated antigen gene in primary human breast carcinomas. , 1989, Cancer research.

[58]  W. Kast,et al.  Fine peptide specificity of cytotoxic T lymphocytes directed against adenovirus‐induced tumours and peptide‐mhc binding , 1991, International journal of cancer. Supplement = Journal international du cancer. Supplement.

[59]  S. Hammarström.  The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. , 1999, Seminars in cancer biology.

[60]  Kuznetsov Va.  A mathematical model for the interaction between cytotoxic T lymphocytes and tumour cells. Analysis of the growth, stabilization, and regression of a B-cell lymphoma in mice chimeric with respect to the major histocompatibility complex. , 1991, Biomedical science.

[61]  Markus R. Owen,et al.  MATHEMATICAL MODELLING OF MACROPHAGE DYNAMICS IN TUMOURS , 1999 .

[62]  D. Lowy,et al.  Papillomaviruses: prophylactic vaccine prospects. , 1999, Biochimica et biophysica acta.

[63]  P. Newsholme,et al.  Macrophage-mediated lysis of a beta-cell line, tumour necrosis factor-alpha release from bacillus Calmette-Guérin (BCG)-activated murine macrophages and interleukin-8 release from human monocytes are dependent on extracellular glutamine concentration and glutamine metabolism. , 1999, Clinical science.

[64]  M. Salgaller.  Monitoring of Cancer Patients Undergoing Active or Passive Immunotherapy , 1997, Journal of immunotherapy.

[65]  T. Rothstein,et al.  Guinea pig antiserum to mouse cytotoxic T lymphocytes and their precursors. , 1978, Journal of immunology.

[66]  J. Uhr,et al.  Dormancy in a model of murine B cell lymphoma. , 2001, Seminars in cancer biology.

[67]  L. Bliss,et al.  Efficacy of BCG vaccine against leprosy and tuberculosis in northern Malawi , 1992, The Lancet.

[68]  R. Gatenby,et al.  Application of competition theory to tumour growth: implications for tumour biology and treatment. , 1996, European journal of cancer.

[69]  P. Musiani,et al.  Tumor Rejection and Immune Memory Elicited by Locally Released LEC Chemokine Are Associated with an Impressive Recruitment of APCs, Lymphocytes, and Granulocytes1 , 2000, The Journal of Immunology.

[70]  F. Burnet.  The concept of immunological surveillance. , 1970, Progress in experimental tumor research.

[71]  N. Breslow,et al.  Latent carcinoma of prostate at autopsy in seven areas. Collaborative study organized by the International Agency for Research on Cancer, Lyons, France , 1977, International journal of cancer.

[72]  W. Clark,et al.  Biomarkers for individual susceptibility to carcinogenic agents: excretion and carcinogenic risk of benzo[a]pyrene metabolites. , 1992, Environmental health perspectives.